<DOC>
	<DOCNO>NCT00976326</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial evaluate pharmacokinetic safety profile NN1250 ( insulin degludec ) alter extent dose adjust subject impair liver function compare dose subject normal liver function .</brief_summary>
	<brief_title>A Trial Investigating Pharmacokinetic ( Mode Action Body ) Safety Profiles NN1250 ( Insulin Degludec ) Subjects With Various Degrees Impaired Liver Function Subjects With Normal Liver Function</brief_title>
	<detailed_description />
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Subject normal hepatic function , liver parameter within normal range . Not assess ChildPugh criterion . Or : Subject stable hepatic impairment classify ChildPugh grade A , B C assess Investigator Body mass index maximum 40.0 kg/m^2 Subject disease condition Investigator feel would interfere trial outcome execution except condition associate hepatic impairment group subject compromise hepatic function Subject donate blood plasma past month 500 mL within 3 month prior screen Not able willing refrain smoking inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>